SONN
Companies
NASDAQ
Sonnet Biotherapeutics Holdings Inc.
Health Care
$1.17
-$0.29 (-19.86%)
Price Chart
Overview
About SONN
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Market Cap
$5.3M
Volume
77.6K
Avg. Volume
56.7K
P/E Ratio
-0.08355615
Dividend Yield
0.00%
Employees
9.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.82
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, SONN shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025